Patient-Directed Discharges / AMA
Christine Hamilton
PDDs have a higher risk of hospital readmission and result in higher mortality rates. If paged from the bedside about a patient requesting to leave “AMA,” call nurse back and then go speak with the patient.
- Address patient concerns (i.e. pain control, substance withdrawal, fear/anxiety, financial strain, diet) to mitigate reversible causes for contention.
- Determine capacity to leave: review risks of leaving and medical reasoning to stay (see Medical Decision-Making Capacity under “Psychiatry”). This discussion should be witnessed by nurse or charge nurse if possible. Provider and patient will need to sign AMA discharge form, which nurse can obtain.
- Send new medications to pharmacy and request hospital follow-up visits if patient leaves
- Sign discharge order. In the “discharge to” section select “left against medical advice” (for more detailed discharge instructions, see appendices)
- Clearly document in discharge summary that patient was informed about the risks of leaving, had the capacity to make the decision to leave, and left prematurely based on your clinical judgement.
- *Caveat: if patient at any point becomes threatening or you feel unsafe, allow them to leave or contact security
Management
- Treatment goals
- Rate control, Goal HR \< 110 (RACE II)
- Rhythm control (if indicated)
- Stroke prevention (CHADS2VASc)
- Sick sinus, Sepsis
Rate control
- RVR ~ sinus tach of AF; Always work to address the underlying cause (infection, volume overload, etc). Rate control is rarely an emergency unless the patient is unstable
- If stable with RVR (SBP >90)
- IV if HR > 130 or symptomatic (metop 5 mg IV or dilt 15-20 mg IV), otherwise do PO
- AV nodal blocking agents
- B-blockers: Start with metop tartrate (titratable) consolidate to succinate. Avoid in decompensated or borderline HF
- Calcium channel blockers (diltiazem): avoid in HFrEF
- Peri stable (SBPs 80s-90 with preserved perfusion)
- Amiodarone: Consider if decompensated HF, accessory pathway, anti-coagulated. Caution that you may cardiovert pt (stroke risk)
- Unstable (SBPs \<80)
- Cardioversion
Rhythm control
- New onset a-fib (first time diagnosis): most pts will be a candidate for trial of cardioversion
- If onset clearly within 48 hours, can proceed without TEE. Often TEE is done anyway (pt may have had intermittent asymp AF)
- If onset >48 hours or unclear, will need TEE to rule out LAA thrombus
- Pharmacologic options include class 1C: flecainide, propafenone (avoid in structural heart disease) and class 3: Amiodarone, dronedarone, sotalol, ibutilide, dofetilide (some require loading inpt)
- Caution using antiarrhythmics in any pt you wouldn't electrically cardiovert without TEE
- Consider EP consult for ablation in symptomatic paroxysmal or persistent AF refractory to anti-arrhythmic drugs, AF in HFrEF, or flutter
Stroke Prevention (for AF and flutter)
- CHA2DS2-VASc risk score >2 in M or >3 in F should prompt long term AC in AF persisting >48 hours
- DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred to warfarin except in moderate to severe MS or mechanical valve
- If cardioversion planned for new onset AF, start AC as soon as possible
- Post-cardioversion, anticoagulate for at least 4 weeks due to atrial stunning and stroke risk
- If no contraindications or procedures, continue anticoagulation while inpatient
- Typically do not need to bridge AC for AF in the setting of procedures unless mechanical valve is present. Decide on a case by-case basis
- Left atrial appendage closure can be considered in those with increased risk of bleeding (WATCHMAN, Amulet devices)
